Sagimet Biosciences (SGMT) Payables (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Payables of $2.3 million for Q1 2026, down 28.54% year-over-year from $3.2 million in Q1 2025, and up 75.94% quarter-over-quarter from $1.3 million in Q4 2025.
Sagimet Biosciences (SGMT) Payables (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Payables history runs 5 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- In Q1 2026, Payables fell 28.54% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 28.54% YoY), while the FY2025 annual figure was $1.3 million, down 8.14% from the prior year.
- Payables for Q1 2026 stood at $2.3 million, up from $1.3 million in the prior quarter.
- The five-year high for Payables was $4.2 million in Q3 2025, with the low at $186000.0 in Q4 2023.
- The 5-year median for Payables is $1.7 million (2023), against an average of $1.8 million.
- The sharpest annual moves came in 2023 and 2024: Payables slumped 83.47% in 2023, then jumped 666.13% in 2024.
- Sagimet Biosciences' Payables stood at $1.1 million in 2022, then plunged by 83.47% to $186000.0 in 2023, then surged by 666.13% to $1.4 million in 2024, then decreased by 8.14% to $1.3 million in 2025, then surged by 75.94% to $2.3 million in 2026.
- Business Quant data shows SGMT's Payables at $2.3 million in Q1 2026, $1.3 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | 4.24 Mn |
| Jun 30, 2025 | 1.92 Mn |
| Mar 31, 2025 | 3.22 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Mar 31, 2024 | 531,000.00 |
| Dec 31, 2023 | 186,000.00 |
| Sep 30, 2023 | 1.70 Mn |
| Jun 30, 2023 | 2.72 Mn |
| Dec 31, 2022 | 1.13 Mn |